AI Drug Discovery for Pharma and Biotech

Drug discovery

4

drugs

With orphan designations

Overview

Hypochondroplasia is a mild skeletal dysplasia caused by FGFR3 mutations, leading to disproportionate short stature, limb shortening, and subtle dysmorphic features. Diagnosis combines clinical assessment, radiography (narrowed lumbar spine, short femoral necks), and genetic testing. Complications include spinal stenosis, leg bowing, and mild neurocognitive issues in ~10% [1][6][14]. Management focuses on monitoring growth, orthopedic interventions, and emerging therapies like vosoritide [3][8][12]. Life expectancy is normal.

Population

  • Incidence ~1:15,000–40,000 births; most cases arise from spontaneous FGFR3 variants (commonly p.N540K) [2][6][9].

Burden

  • Reduced quality of life scores correlating with age/height [4]

  • ~10% risk of learning disabilities; 5–10% seizure risk [2][14]

  • Chronic joint pain and osteoarthritis in adulthood [10][19]

Therapies

  • Orthopedic surgery for spinal/limb complications (rarely needed) [1][14]

  • Growth hormone therapy (limited long-term efficacy) [3][7]

  • Vosoritide (15 μg/kg/day) shown to improve growth velocity by 1.8 cm/year in trials [8][12][16]

Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases

Research Papers

105 drug discovery papers about Hypochondroplasia, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

105 drug discovery papers about Hypochondroplasia, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

2026-01-01 | P237: Incidence of neurocognitive conditions in hypochondroplasia

Hypochondroplasia is one of several well-described skeletal dysplasias that occur along the FGFR3-spectrum. While individuals with hypochondroplasia generally present more mildly from a skeletal perspective than achondroplasia, an increased incidence of attention/hyperactivity concerns, learning, and intellectual disability as well as seizures, has been reported in this population. For counseling and screening purposes there is limited information on both risk of neurocognitive diagnoses and role of MRI as a predictor of neurocognitive outcomes.

Open article ↗



2024-10-01 | 8519 Investigating the Role of Protein Inhibitor of Activated STAT1 (Pias1) in Growth Plate Chondrocyte Maturation

Abstract Disclosure: J. Baronas: None. U. Ahmed: None. J.N. Hirschhorn: None. N.E. Renthal: None. Development of growth plate chondrocytes is a complex process that involves a wide array of regulatory elements. Recently our laboratory conducted a genome wide CRISPR knockout (KO) screen of growth plate chondrocyte maturation to discover novel genes and gene networks in the proliferation and maturation of chondrocytes. Among targets uncovered is Protein Inhibitor of Activated STAT 1 (Pias1), an E3 SUMO ligase that plays a multi-faceted role in genetic regulation, driving post-translational modifications, directly binding to transcription factors, and functioning as a DNA-binding protein. While Pias1 has been shown to be involved in the regulation of many cellular processes across multiple tissues, its function in growth plate development and chondrocyte maturation has been previously unstudied. In our genome-wide screen, our laboratory identified that loss of Pias1 led to early maturation of chondrocytes. This project seeks to investigate the role of Pias1 in chondrocyte maturation and differentiation. We first developed a Pias1-KO chondrocyte cell line, observing upregulation of hypertrophic markers Cd200 and Col10a1 in KOs relative to control via qPCR, in addition to proliferative regulators IHH and Pth1R. Through Bulk-RNAseq of the same cell line, we identified additional chondrocyte markers as upregulated in KO, as well as osteoblast marker Sp7. Members of the HoxD family, regulators of limb development, were downregulated. Cell culture data suggests that loss of Pias1 leads to increased cell proliferation and increased matrix production, indicating dysregulation of multiple chondrocyte processes. Immunohistochemistry of micromass culture sections also suggests morphological differences between KO and control, with KO cells significantly larger in diameter. Early SUMO-1 profiling yields limited evidence of decreased global SUMOylation in KO cells, one possible mechanistic explanation for the observed dysregulation. Ongoing studies are focused on identifying specific SUMOylation targets of Pias1 in chondrocytes, analyzing proteomic differences in KO and control, seeking putative DNA-binding sites of Pias1, and observing in vivo murine Pias1-KO growth plates. Our findings suggest that PIAS1 plays a crucial role in the growth plate by prolonging growth and delaying terminal hypertrophy. Our study aims to provide a better understanding of the regulatory pathways involved in growth plate development and related phenotypes such as height, and contribute to the development of novel therapies for growth-related disorders, such as achondroplasia and hypochondroplasia. Presentation: 6/1/2024

Open article ↗



2026-01-01 | P237: Incidence of neurocognitive conditions in hypochondroplasia

Hypochondroplasia is one of several well-described skeletal dysplasias that occur along the FGFR3-spectrum. While individuals with hypochondroplasia generally present more mildly from a skeletal perspective than achondroplasia, an increased incidence of attention/hyperactivity concerns, learning, and intellectual disability as well as seizures, has been reported in this population. For counseling and screening purposes there is limited information on both risk of neurocognitive diagnoses and role of MRI as a predictor of neurocognitive outcomes.

Open article ↗



2024-10-01 | 8519 Investigating the Role of Protein Inhibitor of Activated STAT1 (Pias1) in Growth Plate Chondrocyte Maturation

Abstract Disclosure: J. Baronas: None. U. Ahmed: None. J.N. Hirschhorn: None. N.E. Renthal: None. Development of growth plate chondrocytes is a complex process that involves a wide array of regulatory elements. Recently our laboratory conducted a genome wide CRISPR knockout (KO) screen of growth plate chondrocyte maturation to discover novel genes and gene networks in the proliferation and maturation of chondrocytes. Among targets uncovered is Protein Inhibitor of Activated STAT 1 (Pias1), an E3 SUMO ligase that plays a multi-faceted role in genetic regulation, driving post-translational modifications, directly binding to transcription factors, and functioning as a DNA-binding protein. While Pias1 has been shown to be involved in the regulation of many cellular processes across multiple tissues, its function in growth plate development and chondrocyte maturation has been previously unstudied. In our genome-wide screen, our laboratory identified that loss of Pias1 led to early maturation of chondrocytes. This project seeks to investigate the role of Pias1 in chondrocyte maturation and differentiation. We first developed a Pias1-KO chondrocyte cell line, observing upregulation of hypertrophic markers Cd200 and Col10a1 in KOs relative to control via qPCR, in addition to proliferative regulators IHH and Pth1R. Through Bulk-RNAseq of the same cell line, we identified additional chondrocyte markers as upregulated in KO, as well as osteoblast marker Sp7. Members of the HoxD family, regulators of limb development, were downregulated. Cell culture data suggests that loss of Pias1 leads to increased cell proliferation and increased matrix production, indicating dysregulation of multiple chondrocyte processes. Immunohistochemistry of micromass culture sections also suggests morphological differences between KO and control, with KO cells significantly larger in diameter. Early SUMO-1 profiling yields limited evidence of decreased global SUMOylation in KO cells, one possible mechanistic explanation for the observed dysregulation. Ongoing studies are focused on identifying specific SUMOylation targets of Pias1 in chondrocytes, analyzing proteomic differences in KO and control, seeking putative DNA-binding sites of Pias1, and observing in vivo murine Pias1-KO growth plates. Our findings suggest that PIAS1 plays a crucial role in the growth plate by prolonging growth and delaying terminal hypertrophy. Our study aims to provide a better understanding of the regulatory pathways involved in growth plate development and related phenotypes such as height, and contribute to the development of novel therapies for growth-related disorders, such as achondroplasia and hypochondroplasia. Presentation: 6/1/2024

Open article ↗



Access all drug discovery articles and probability of success in trials forecasts:

Access all drug discovery articles and probability of success in trials forecasts:

Drug Discovery Landscape

4 orphan drug designations for Hypochondroplasia.

4 orphan drug designations for Hypochondroplasia.

Drug

Therapy type

Regulator

Orphan designation

Approval

Sponsor

Infigratinib

small molecules

EMA

2025-11-21

BridgeBio Europe B.V.

infigratinib

small molecules

FDA

2025-06-03

QED Therapeutics, Inc

Vosoritide

peptides

EMA

2024-12-13

BioMarin International Limited

vosoritide

peptides

FDA

2023-08-01

BioMarin Pharmaceutical Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.